USPTO serial 79365161
AMESOPAX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 13, 2024
- Examiner
- CERDA, VICTOR
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AMESOPAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sean K. Owens
Sean K. Owens Wood Herron & Evans LLP600 Vine StreetSuite 2800Cincinnati, OH 45202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for scientific use; stem cells for research use; cell growth media for growing cells for scientific use; stem cells other than for medical or veterinary purposes, namely, stem cells for aesthetic purposes excluding all medical or veterinary purposes | ACTIVE | — |
| 005 | Drugs for medical purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for treating skin disorders; diagnostic agents, namely, diagnostic radiopharmaceutical agent for use in PET imaging; pharmaceutical preparations, namely, pharmaceutical preparations for treating skin disorders; preparations for medical purposes, namely, pharmaceutical preparations for treating skin disorders; preparations for biomedical purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical cell preparations for treating skin disorders; substances for medical use, namely, pharmaceutical preparations for treating skin disorders; substances for biomedical purposes, namely, pharmaceutical preparations for treating skin disorders; live implants for pharmaceutical purposes, namely, implants comprising living tissue for pharmaceutical purposes; biochemical and chemical products for medical use, namely, pharmaceutical preparations for treating skin disorders; biochemical and chemical products for pharmaceutical purposes, namely, pharmaceutical preparations for treating skin disorders; biochemical and chemical diagnostic preparations for medical purposes; proteins for medical purposes, namely, protein arrays for medical diagnosis purposes; biological preparations for medical and veterinary purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical and veterinary preparations for external and systemic use, namely, pharmaceutical preparations for treating skin wounds; biological, pharmaceutical and veterinary preparations for skin care for medical purposes, namely, pharmaceutical preparations for treating skin disorders; medical dressings; preparations for wound treating and healing, namely, pharmaceutical preparations for treating skin wounds; pharmaceutical preparations for treating skin wounds; stem cells for medical purposes; stem cells for veterinary purposes; somatic stem cell therapeutics, namely, somatic stem cells for medical or veterinary use; cells for medical use in the nature of fibroblasts for medical purposes; cells for medical use in the nature of fibroblasts for surgical beauty purposes; pharmaceutical implants, namely, implantable pharmaceutical preparations for treating cancer; cells for medical use in the nature of surgical implants derived from stem cells; cells for medical use in the nature of surgical implants derived from fibroblasts; cells for medical use in the nature of biological tissue for implantation; growth media for culturing cells for medical purposes; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, living cells for medical use; biotechnologically engineered tissue products, namely, cells for medical use | ACTIVE | — |
| 042 | Pharmaceutical drug development; scientific and technological services, namely, scientific research in the field of genetics; research and development services in the fields of cell diagnostics, cell therapy; scientific research for medical purposes in the field of genetics; stem cell research services; scientific research; scientific research and development; scientific research, testing and analysis services in the field of genetics; medical research; biomedical research services; research and development in the field of biotechnology; research and development in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development of new products; industrial process research, namely, research and development of new products; research and development of new products for the pharmaceutical industry; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information about medical and scientific research for pharmaceutical products; preparation of reports relating to scientific research | ACTIVE | — |
| 044 | Medical services; medical diagnostic testing, monitoring and reporting services; medical assistance; health clinic services; hospital services; plastic and cosmetic surgery; medical therapies, namely, providing laser therapy for treating medical conditions; medical services in the field of regenerative medicine; medical services relating to the cultivation and procurement of stem cells; medical services in connection with the cultivation and procurement of stem cells | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by RHEACELL GmbH & Co. KG
- Other trademarks owned by RHEACELL GmbH & Co. KG
- Other trademarks owned by RHEACELL GmbH & Co. KG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named AMESOPAX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 14, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 22, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 4, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 3, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 13, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 13, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 13, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 28, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 28, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 8, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 18, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 18, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 17, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 17, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 13, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 24, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 24, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 13, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 12, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 17, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 16, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |